Lv1
30 积分 2023-11-21 加入
Cost of Disease Progression in Diffuse Large B-Cell Lymphoma After Frontline Treatment With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
11天前
已完结
Toxicity and response criteria of the Eastern Cooperative Oncology Group
11天前
已完结
Isocitrate Dehydrogenase Inhibitors in Acute Myeloid Leukemia
11天前
已完结
Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study
14天前
已完结
High expression of Bcl-2 predicts poor outcome in diffuse large B-cell lymphoma patients with low international prognostic index receiving R-CHOP chemotherapy
17天前
已完结
Aldosterone and aldosterone synthase inhibitors in cardiorenal disease
1个月前
已完结
Aldosterone and Aldosterone Modulation in Cardio-Kidney Diseases
1个月前
已完结
Aldosterone and arterial hypertension
1个月前
已完结
Efficacy and relapse profiles of Pola‐R‐ CHP versus R‐ CHOP in previously untreated diffuse large B‐cell lymphoma: A multicentre real‐world study
1个月前
已完结
Efficacy and Safety of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Previously Untreated Diffuse Large B‐Cell Lymphoma: A Real‐World, Multi‐Center, Retrospective Cohort Study
1个月前
已完结
皖公网安备34019202002308
